Second Sight Medical Products

Equities

EYES

US81362J3086

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
1.67 ^USD	+2.45%		-16.29%	-26.75%

2022	Vivani Medical Starts Nasdaq Trading Lower	MT
2022	Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index	CI

Second Sight Appoints Gregg Williams as Chairman of the Board of Directors

March 16, 2018 at 05:30 pm IST

Second Sight Medical Products, Inc. announced that the Board of Directors has appointed Mr. Gregg Williams as Chairman of the Board, effective immediately. Mr. Williams, a current member of the Board of Directors of Second Sight and the Company’s large shareholder succeeds Dr. Robert “Bob” Greenberg, who has served as Chairman of the Board of Directors since August 2015 and who remains a member of the Board.

Latest news about Second Sight Medical Products

Vivani Medical Starts Nasdaq Trading Lower	31/22/31	MT
Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index	31/22/31	CI
Second Sight Medical Completes Merger With Nano Precision Medical; Changes Name to Vivani Medical	30/22/30	MT
Nano Precision Medical, Inc. completed the acquisition of Second Sight Medical Products, Inc. in a reverse merger transaction.	30/22/30	CI
Second Sight Medical Products Starts Trading on Split-Adjusted Basis; Shares Down	19/22/19	MT
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Second Sight Medical Products, Inc. Announces Resignation of Edward Randolph as its Chief Operating Officer, Effective August 19, 2022	06/22/06	CI
Second Sight Medical Products, Inc. has Changed its Name to Vivani Medical, Inc	27/22/27	CI
Second Sight Medical Products Receives $1.1 Million of Funding for Visual Cortical Prosthesis Trial	18/22/18	MT
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study	18/22/18	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
North American Morning Briefing : Dow Futures -2-	25/22/25	DJ
North American Morning Briefing : Stock Futures -3-	18/22/18	DJ
Transcript : Nano Precision Medical, Inc., Second Sight Medical Products, Inc. - M&A Call	08/22/08
Second Sight Medical Products to Acquire Nano Precision Medical in All-Stock Deal	08/22/08	MT
Nano Precision Medical, Inc. entered into term sheet to acquire Second Sight Medical Products, Inc. for approximately $180 million in a reverse merger transaction.	07/22/07	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	13/21/13	CI
Second Sight Medical Products, Inc.(NasdaqCM:EYES) added to S&P Global BMI Index	20/21/20	CI
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	14/21/14	CI
Second Sight Medical Products : Obtains New NIH Grant Supplement for Visual Neuroprostheses Study	11/21/11	MT
Second Sight Medical Products, Inc. Receives Grant from the National Institutes of Health	05/21/05	CI
North American Morning Briefing : Stock Futures -3-	23/21/23	DJ
Certain Common Stock of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	23/21/23	CI
Certain Stock Options of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	23/21/23	CI
Certain Warrants of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.	23/21/23	CI

Chart Second Sight Medical Products

Duration

Period

More charts

Company Profile

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.

Sector

More about the company